Core Viewpoint - The company has received a medical device registration certificate for its Heparin Binding Protein (HBP) assay kit, which is expected to enhance its product portfolio and core competitiveness, although it will not have a significant impact on recent operations and performance [1]. Group 1 - The product is a Heparin Binding Protein assay kit using the latex immunoturbidimetric method [1]. - The registration certificate was issued by the Beijing Drug Administration, with the registration number 京械注准20252400796 [1]. - The registration falls under Class II medical devices and is valid until August 31, 2030 [1]. Group 2 - The acquisition of this registration certificate enriches the company's product categories [1]. - It is expected to have a positive impact on the company's future development [1]. - However, it is noted that there will be no major impact on the company's recent operations and performance [1].